MetaCap

DBV Technologies S.A. (DBVT) vs Electra Therapeutics (ETRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

DBV Technologies S.A. is the larger company by market cap ($566.8 million vs $509.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DBVT-26.96%ETRA-38.79%
+8%-20%-47%
Sep 18, 20261 yearNov 20, 2026
DBVT-26.96%ETRA-38.79%
+2%-21%-43%
Sep 14, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DBVT versus ETRA key metrics
MetricDBVTETRA
Share price$9.02$8.11
Market cap$566.82M$509.85M
1-day change-4.25%-9.28%
YTD return-52.95%—
1-year return-34.40%—
5-year return+50.33%—
EPS (TTM)$-3.00$-35.94
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$5.64M—
Revenue growth (YoY)+35.77%—
Net income (latest FY)$-146.95M—
Operating margin-2609.23%—
Net margin-2607.29%—
52-week high$26.19$15.50
52-week low$8.63$6.87
Distance from 52-week high-65.55%-47.68%
Analyst consensusbuystrong_buy
Avg. price target upside+305.10%+309.37%
Average volume352.88K559.28K
Shares outstanding62.84M62.87M
Employees17946
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About DBV Technologies S.A.

DBVT stock →

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 179 employees

About Electra Therapeutics

ETRA stock →

Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees

DBVT vs ETRA FAQ

Which is bigger, DBV Technologies S.A. or Electra Therapeutics?

DBV Technologies S.A. (DBVT) is larger, with a market capitalization of $566.82M compared with $509.85M for Electra Therapeutics (ETRA).

Are DBV Technologies S.A. and Electra Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons